Business
Regen BioPharma, Inc. Retains Objective Capital Partners, LLC to Explore Non-Dilutive Funding Opportunities
Regen BioPharma, Inc. Retains Objective Capital Partners, LLC to Explore Non-Dilutive Funding Opportunities.
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nRegen BioPharma, Inc. Retains Objective Capital Partners, LLC to Explore Non-Dilutive Funding Opportunities\n\n\n\n\n\nRegen BioPharma, Inc. Retains Objective Capital Partners, LLC to Explore Non-Dilutive Funding Opportunities\nCo-development and partnership relationships to be major focus of funding arrangements\nPR Newswire\nSAN DIEGO, June 7, 2016\n\n\n\nSAN DIEGO, June 7, 2016 /PRNewswire/ --\n\nRegen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today that it has retained Objective Capital Partners, LLC as its advisor to assist the company in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide a source of non-dilutive funding.  The strategies being explored include partnering assets of the Company with the goal to provide a source of non-dilutive funding to primarily support Regen's NR2F6 tCellVax and small molecule programs.\n\n\"We have several material assets whose monetization in the near term can support the growth needs of our NR2F6 programs.  Our most advanced therapeutic asset, HemaXellerate, may be of particular interest to strategic partners interested in rare diseases as it is FDA-cleared for testing in aplastic anemia patients,\" said David Koos, Ph.D., Chief Executive Officer.  \"Among our programs, the NR2F6 program has by far the most potential value to patients and our shareholders.  We need to make sure we have the financing in place to execute on management's plan to advance the NR2F6 program to the point where Big Pharma will be interested in this asset.\"\n\nRegen BioPharma's pipeline includes autologous cell therapies (HemaXellerate, dCellVax, tCellVax), universal donor cell therapy (ucVax) and small molecules (NR2F6 program). HemaXellerate is the subject of an FDA-cleared IND and Phase I/II clinical trial that is intended to determine safety and potential efficacy of intravenously administered autologous stromal vascular fraction (SVF) cells in patients with severe, immune suppressive refractory aplastic anemia. The Company also intends to amend its IND and pursue a Phase I/II clinical trial assessing HemaXellerate in patients suffering from chemotherapy-induced bone marrow suppression. As reported previously, HemaXellerate is being tested at the Pan Am Cancer Treatment Center in Mexico in a first-i...